Research Overview
Sequence and physical character
Leucine at position four makes AEDL the least polar of the Ala-Glu-Asp peptides. In practical terms that shows up as later elution on reversed-phase HPLC and a different solubility ceiling from Cardiogen or Cortagen, which matters when a single analytical method is used across the series.
Bronchial epithelium models
Published work has applied AEDL to cultured bronchial epithelial cells and to organotypic lung preparations, measuring proliferation, viability, and expression of markers linked to epithelial differentiation and mucosal maintenance. Reported effects are concentration-dependent and drawn from a modest number of studies.
Rodent lung studies
Animal experiments in the source literature examine lung histology and selected biochemical markers, sometimes in models involving inhaled irritants or age-related tissue change. These reports are descriptive and were generally not designed to separate a direct epithelial effect from broader systemic responses.
Comparative work across the series
Bronchogen is often included when investigators run the whole Ala-Glu-Asp set in one assay to probe the tissue-specificity claim. Holding the assay constant across three closely related sequences is the most informative design available in this literature, and it is where a new researcher is best advised to start.
Evidence and controls
Independent replication of AEDL results outside the originating programme is limited, and published group sizes are small. Any follow-up should include a vehicle control and, where possible, a scrambled-sequence peptide, since the whole claim rests on sequence specificity rather than a generic peptide effect. It is also worth confirming peptide stability under the culture or exposure conditions being used, because short peptides in serum-containing media are open to rapid aminopeptidase cleavage, and an apparent lack of effect can as easily reflect degradation as inactivity.
